Last updated on August 2019

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer


Brief description of study

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with carboplatin/pemetrexed with or without pembrolizumab and AB122 monotherapy in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

Detailed Study Description

Dose escalation of AB928 in combination with carboplatin/pemetrexed and AB928 in combination with carboplatin/pemetrexed plus pembrolizumab at standard doses will be assessed in participants with advanced metastatic non-squamous Non-Small Cell Lung Cancer. In this dose escalation combination study, participants will receive oral administration of AB928 as well as IV infused carboplatin/pemetrexed with or without pembrolizumab.

Dose expansion of AB928 in combination with carboplatin/pemetrexed and AB928 in combination with carboplatin/pemetrexed plus pembrolizumab at standard doses may be assessed in participants with advanced metastatic non-squamous Non-Small Cell Lung Cancer. The dose of AB928 used will be determined based on the findings from the dose escalation phase.

Concurrently, AB122 monotherapy will be assessed in participants with advanced non-squamous Non-Small Cell Lung Cancer.

Overall duration of treatment will depend on how well the treatment is tolerated.

Treatment may continue until unacceptable toxicity or progressive disease or other reasons specified in the protocol.

Clinical Study Identifier: NCT03846310

Find a site near you

Start Over

Fairfax, Virginia

Fairfax, VA United States
5.27miles
  Connect »